News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Kim M. Hirshfield

Articles by Kim M. Hirshfield

TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

BySara M. Tolaney, MD, MPH,Paolo D’Amico,Liyi Jia,Kim M. Hirshfield,Fatima Cardoso

April 16th 2025

Latest Updated Articles

Trending on CancerNetwork

FDA Grants Approval to Teclistamab Combo in RRMM

Cadonilimab Yields 100% 24-Month OS in Recurrent Cervical Cancer Population

Trifluridine/Tipiracil-Associated Neutropenia Associated With Improved Outcomes in mCRC

Namodenoson Meets Primary Safety End Point in Pretreated PDAC

Comparable Ipilimumab/Nivolumab Outcomes Observed in Older RCC Population